GSK Press Releases - EIN Presswire - Press Release Distribution Service

Published on June 4, 2012 - 08:10 GMT

GSK presents positive results for investigational BRAF and MEK inhibitors dabrafenib and trametinib at ASCO

Issued: Monday 04 June 2012, London UK Phase III studies of single agent therapy in metastatic melanoma with BRAF V600 mutations meet primary endpoints Findings from GlaxoSmithKline (GSK) plc’s Phase III clinical study programme evaluating single agent …

Distribution channels: Companies

Published on June 1, 2012 - 13:10 GMT

GSK announces expiration of Hart-Scott-Rodino waiting period for tender offer for HGS

Issued: Friday 01 June 2012, London UK GlaxoSmithKline plc (LSE: GSK) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976 (the “HSR Act”), as amended, has expired with respect to GSK’s tender offer for …

Distribution channels: Companies

Published on May 31, 2012 - 12:10 GMT

GSK and EPSRC announce creation of new Chair in Sustainable Chemistry at the University of Nottingham

Issued: Thursday 31 May 2012, London UK GlaxoSmithKline (GSK) and The Engineering and Physical Sciences Research Council (EPSRC) today announced that they will jointly contribute to the funding for a Chair in Sustainable Chemistry to be based at the …

Distribution channels: Companies

Published on May 30, 2012 - 14:12 GMT

Regulatory Update – GSK announces submissions in the EU & US for new indications for Promacta®/Revolade®

Issued: Wednesday 30 May 2012, London UK GlaxoSmithKline plc announced today that it has submitted regulatory applications in the European Union and United States related to eltrombopag (Promacta®/Revolade® ) and its use to increase platelet counts in …

Distribution channels: Companies

Published on May 29, 2012 - 23:12 GMT

GlaxoSmithKline confirms US District Court ruling in Pronova BioPharma’s favour on Lovaza™ patents

Issued: Tuesday 29 May 2012, London, UK GlaxoSmithKline plc (GSK) which has the marketing rights for Lovaza (omega-3-acid ethyl esters) in the US and Puerto Rico, confirmed that U.S. District Judge Sue Lewis Robinson, the presiding judge in the U.S. …

Distribution channels: Companies

Published on May 29, 2012 - 14:12 GMT

GSK announces start of Phase III programme for combination of dabrafenib (GSK2118436) and trametinib (GSK1120212) in BRAF V600 ...

Issued: Tuesday 29 May 2012, London UK GlaxoSmithKline plc. today announced the start of a Phase III programme evaluating the combination of dabrafenib, its BRAF inhibitor, and trametinib, its MEK inhibitor, in patients with BRAF mutation-positive …

Distribution channels: Companies

Published on May 29, 2012 - 12:12 GMT

GSK secures future of local playing fields with Fields in Trust as part of London 2012 legacy

Issued: Tuesday 29 May 2012, London UK GSK has today entered a partnership with Fields in Trust (FIT) to secure the future of its Swyncombe Avenue Playing Fields, where hundreds of local people already enjoy sport, by placing them into trust in …

Distribution channels: Companies

Published on May 25, 2012 - 14:11 GMT

GSK receives positive opinion from European CHMP for pazopanib in the treatment of patients with certain advanced soft tissue ...

Issued: Friday 25 May 2012, London UK GlaxoSmithKline. plc (GSK) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for …

Distribution channels: Companies

Published on May 24, 2012 - 08:10 GMT

Innovative public-private collaboration launches to tackle antibiotic research

Issued: Thursday 24 May 2012, London UK New €224m (£180m) funding to enable development of antibiotics for bacterial infections and drive unprecedented information sharing GlaxoSmithKline and AstraZeneca today welcomed the launch of a pioneering …

Distribution channels: Companies

Published on May 18, 2012 - 12:10 GMT

Two overall winners announced at prestigious national award ceremony in London’s Science Museum

Issued: Friday 18 May 2012, London UK For the first time in its 15 year history the judges of the GlaxoSmithKline (GSK) IMPACT Awards could not choose one overall winner for the awards so instead awarded two prizes. The accolade was received by …

Distribution channels: Companies

Published on May 17, 2012 - 17:10 GMT

GSK statement on tender offer to acquire Human Genome Sciences

Issued: Thursday 17 May 2012, London UK GlaxoSmithKline plc (LSE: GSK) today commented on Human Genome Sciences (NASDAQ: HGSI) Board of Directors' decision to recommend against GSK’s tender offer to acquire all of the outstanding shares of HGS for …

Distribution channels: Companies

Published on May 16, 2012 - 14:13 GMT

GlaxoSmithKline completes transaction to increase its ownership in Theravance

Issued: Wednesday 16 May 2012, London, UK & South San Francisco, CA GlaxoSmithKline plc (“GSK”) (LSE:GSK) and Theravance, Inc. (“Theravance”) (NASDAQ: THRX) announced today that following approval by Theravance, Inc.‟s stockholders at their Annual …

Distribution channels: Companies

Published on May 15, 2012 - 09:10 GMT

GlaxoSmithKline to fully acquire Cellzome for £61 million

Issued: Tuesday 15 May 2012, London UK GSK to further expand its platform technology expertise with acquisition of chemical proteomics company GlaxoSmithKline plc (GSK) today announced that it has entered into an agreement to acquire those shares it …

Distribution channels: Companies

Published on May 14, 2012 - 21:10 GMT

GSK statement on BBC Panorama broadcast: ‘the truth about tax’

Issued: Monday 14 May 2012, London UK GSK issued the following statement in response to the BBC Panorama programme related to Corporation Tax payments in the UK and Luxembourg broadcast tonight, Monday 14 May 2012. “GSK is very disappointed with …

Distribution channels: Companies

Published on May 12, 2012 - 00:11 GMT

Stiefel receives US FDA approval of Fabior™ Foam, 0.1%

Issued: Friday 11 May 2012, Research Triangle Park, NC Stiefel, a GSK (NYSE:GSK) company, today announced that the US Food and Drug Administration has approved the New Drug Application for Fabior (tazarotene) Foam, 0.1%. Itis the only retinoid in a …

Distribution channels: Companies

Published on May 10, 2012 - 12:10 GMT

GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash

Issued: Thursday 10 May 2012, London UK GlaxoSmithKline plc (LSE: GSK) today announced that it has commenced its previously announced tender offer to acquire all of the outstanding shares of Human Genome Sciences (NASDAQ: HGSI) for US$13.00 per share in …

Distribution channels: Companies

Published on May 9, 2012 - 07:10 GMT

GSK to commence tender offer to acquire Human Genome Sciences for US $13.00 per share in cash

Issued: Wednesday 09 May 2012, London, UK GlaxoSmithKline plc (LSE: GSK) today announced that it will not participate in Human Genome Sciences (NASDAQ: HGSI) strategic alternatives review process and will instead commence a tender offer this week …

Distribution channels: Companies

Published on May 4, 2012 - 10:13 GMT

James Shannon named GlaxoSmithKline Chief Medical Officer

Issued: Friday 04 May 2012, London UK James Shannon has been named GSK’s Chief Medical Officer (CMO), effective 1 May. James will report to R&D Chairman Moncef Slaoui and be based in London. He will be accountable for medical governance and …

Distribution channels: Companies

Published on May 3, 2012 - 13:11 GMT

GlaxoSmithKline plc appoints two Non-Executive Directors to its Board

Issued: Thursday 03 May 2012, London UK GlaxoSmithKline plc (GSK) announces that Ms. Lynn Elsenhans and Ms. Jing Ulrich will join the Board of the Company with effect from 1 July 2012 as Non-Executive Directors. Ms. Elsenhans was Chair, President …

Distribution channels: Companies

Published on May 1, 2012 - 13:13 GMT

GlaxoSmithKline and Yale University establish drug discovery collaboration to design potential new class of medicines

Issued: Tuesday 01 May 2012, London UK and Phildelphia USA GlaxoSmithKline plc (GSK) and Yale University have established a drug discovery research collaboration to design a potential new class of medicines that degrade disease-causing proteins. …

Distribution channels: Companies